

# Sherrie Bhoori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754208/publications.pdf>

Version: 2024-02-01

44  
papers

5,764  
citations

218381

26  
h-index

253896

43  
g-index

45  
all docs

45  
docs citations

45  
times ranked

5961  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods. <i>Cancers</i> , 2022, 14, 959.	1.7	11
2	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	1.5	2
3	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference. <i>Transplantation</i> , 2022, 106, e30-e45.	0.5	29
4	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. <i>Transplantation</i> , 2021, 105, 2579-2586.	0.5	13
5	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
6	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
7	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	1.3	12
8	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	2.1	85
9	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
10	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs—a <i>post-hoc</i> analysis. <i>Transplant International</i> , 2020, 33, 917-924.	0.8	4
11	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1143-1149.	0.5	41
12	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
13	Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. <i>Hepatology</i> , 2018, 68, 775-777.	3.6	8
14	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
15	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	1.1	15
16	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	1.8	7
17	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. <i>Liver International</i> , 2017, 37, 678-683.	1.9	10
18	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	1.1	8

#	ARTICLE	IF	CITATIONS
19	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. American Journal of Transplantation, 2016, 16, 2892-2902.	2.6	151
20	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver International, 2016, 36, 1033-1042.	1.9	28
21	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 645-653.	1.4	71
22	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. Endoscopy, 2016, 48, E40-E41.	1.0	4
23	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. JAMA Surgery, 2016, 151, 846.	2.2	106
24	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. Transplantation, 2016, 100, 116-125.	0.5	339
25	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	0.8	57
26	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. Liver International, 2015, 35, 2187-2193.	1.9	2
27	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. Transplant International, 2015, 28, 1055-1065.	0.8	7
28	Repeated transarterial chemoembolization: An overfitting effort?. Journal of Hepatology, 2015, 62, 1440-1442.	1.8	18
29	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1718-1738.	3.3	128
30	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical Radiological Outcomes and Safety Profile. CardioVascular and Interventional Radiology, 2015, 38, 129-134.	0.9	59
31	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 322-328.	0.9	21
32	Current challenges in liver transplantation for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 867-879.	1.0	30
33	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. Journal of Hepatology, 2013, 59, 59-66.	1.8	128
34	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology, 2013, 57, 1826-1837.	3.6	428
35	Resection of hepatocellular cancer $\leq$ 2 cm: Results from two Western centers. Hepatology, 2013, 57, 1426-1435.	3.6	326
36	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. Liver Transplantation, 2011, 17, S44-S57.	1.3	471

#	ARTICLE	IF	CITATIONS
37	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. <i>Transplant International</i> , 2010, 23, 712-722.	0.8	45
38	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. <i>Journal of Hepatology</i> , 2010, 52, 771-775.	1.8	82
39	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
40	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	0.7	249
41	First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation?. <i>Transplantation Proceedings</i> , 2007, 39, 2271-2273.	0.3	15
42	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	3.6	347
43	Role of Home Parenteral Nutrition in Chronic Radiation Enteritis. <i>American Journal of Gastroenterology</i> , 2006, 101, 374-379.	0.2	36
44	Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 49-56.	2.4	40